Strategic partnerships NEC OncoImmunity is actively expanding collaborations with industry players (Transgene, AGC Biologics) and academic partners (Nagasaki University), signaling openness to licensing, co-development, and contract research opportunities to accelerate neoantigen vaccine and personalized immunotherapy programs.

Neoantigen platform The company specializes in AI-driven neoantigen prediction and patient-specific vaccine targets, creating sales potential for software licenses, data-access partnerships, and consulting services that enable faster, clinically actionable immunotherapy decisions.

DNA vaccine focus Development of NECVAX-NEO1, an orally administered DNA vaccine using bacteria to deliver tumor neoantigens, opens avenues to sell vaccine development services, GMP-ready platforms, and collaboration on clinical-stage programs.

Funding signal Recent private financing and CEPI-backed funding history indicate investor confidence and potential leverage for co-development grants, strategic investments, or sponsored research opportunities to de-risk joint vaccine initiatives.

Global reach With a diverse, international team across 13+ countries and active cloud-based tech stack, there are opportunities to sell remote collaboration tools, data analytics services, and scalable cloud-hosted solutions that support multi-site immunotherapy programs.